Bristol-Myers Squibb Company Total Debt 2008–2025
Bristol-Myers Squibb Company reported $47.09B of total debt (short- plus long-term borrowings) for fiscal 2025. That was 8.5% lower than fiscal 2024. Compared with fiscal 2020, the change was -10.6%.
| Fiscal year | Total Debt | Change (YoY) |
|---|---|---|
| FY 2025 | $47.09B | -8.5% |
| FY 2024 | $51.48B | +20.7% |
| FY 2023 | $42.65B | -1.3% |
| FY 2022 | $43.22B | -12.4% |
| FY 2021 | $49.32B | -6.4% |
| FY 2020 | $52.68B | +6.4% |
| FY 2019 | $49.50B | +475.7% |
| FY 2018 | $8.60B | +8.0% |
| FY 2017 | $7.96B | +36.7% |
| FY 2016 | $5.83B | -12.9% |
| FY 2015 | $6.69B | -14.6% |
| FY 2014 | $7.83B | -6.1% |
| FY 2013 | $8.34B | +3.5% |
| FY 2012 | $8.06B | +46.7% |
| FY 2011 | $5.49B | +0.8% |
| FY 2010 | $5.45B | -14.4% |
| FY 2009 | $6.36B | -5.6% |
| FY 2008 | $6.74B | — |
Source: Bristol-Myers Squibb Company SEC filings — balance sheet (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open BMY 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Bristol-Myers Squibb Company reported $47.09B of total debt (short- plus long-term borrowings) for fiscal 2025. That was 8.5% lower than fiscal 2024. Compared with fiscal 2020, the change was -10.6%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Bristol-Myers Squibb Company
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeBristol-Myers Squibb Company — frequently asked questions
What is Bristol-Myers Squibb Company's total debt (short- plus long-term borrowings)?
Bristol-Myers Squibb Company (BMY) reported total debt (short- plus long-term borrowings) of $47.09B for fiscal year 2025, per its SEC filings.
How has Bristol-Myers Squibb Company's total debt (short- plus long-term borrowings) changed over time?
Between fiscal 2008 and 2025, BMY's total debt (short- plus long-term borrowings) grew at roughly 12.1% per year (compound annual rate), from $6.74B to $47.09B.
Where does this data come from?
Figures are computed from Bristol-Myers Squibb Company's official SEC filings (balance sheet (10-K)), refreshed nightly. Not investment advice.
More BMY financial history
Full BMY fundamentals page → · Analyze total debt (short- plus long-term borrowings) with a free tool → · All 1,500+ companies →